News and Trends 28 Dec 2016 Discussing the Future of Personalized Medicine with Biotech Experts Personalized medicine has been a popular topic in the last few years, but when will it materialize? Experts discussed the current challenges at Labiotech Refresh. Jean-Pol Detiffe is the CEO of OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment. In his opinion, one of the main challenges in the […] December 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2016 The 8 Biggest Biotech Medical Fails of 2016 in Europe Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […] December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2016 BMS Offers €850M for a British Oncolytic Virus better than CAR-T BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […] December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 22 Dec 2016 The 10 Biggest Clinical Success Stories of 2016 in European Biotech What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […] December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2016 Mini-Organs grown in Switzerland are Here to Change Drug Discovery This week we travel to Lausanne, a thriving biotech hub in Switzerland. Here, QGel is working to replicate the complexity of life in vitro in lab-grown mini-organs to improve drug discovery. Cool, right? City: Lausanne, Switzerland Founded: 2009 Employees: 11-50 Financial data: Total of €12M raised (12/2016) Mission: QGel creates personalized arrays that can mimic the cellular architecture of different organs. […] December 16, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2016 Young Immuno-Oncology Biotechs attract Funding to Cure Metastasis Amcure and TILT Biotherapeutics announced yesterday new financing rounds supporting the development of unique strategies to cure cancer metastasis. Amcure, in Germany, is fighting highly metastatic forms of cancer by targeting angiogenesis. The company just closed a Series B round with a total of €6M from already existing investors. With the funds, Amcure plans to accelerate […] December 16, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2016 Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials Kiadis Pharma has received approval to test in the UK an immune therapy to address the big challenges of bone marrow transplants, currently the only cure for blood cancers. Kiadis Pharma, based in Amsterdam, is working on therapies to improve the outcome of hematopoietic stem cell transplantation (HSCT), a common treatment for multiple types of […] December 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 Liquid Biopsies: Lowering the Defenses of Resistant Lung Cancer In response to new treatments, cancer came back stronger and more resistant than ever. Medicine’s counterattack will be more effective with a clear target. How do you solve a problem like drug resistance in cancer research? There’s no clear-cut answer yet, not least because the disease can vary so widely. But there has been some […] December 14, 2016 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 Swedish Therapy targeting All Solid Tumors enrolls First Patient Immunicum just received FDA approval to start clinical trials in the US for a therapy that could overcome the challenges of T-cell therapies and target virtually any injectable solid tumor. Immunicum is a biotech from Gothenburg, Sweden, that focuses on immuno-oncology with a different approach from most companies. Instead of T-cells, the company engineers dendritic […] December 14, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2016 What do the CAR-T Patient Deaths Mean for the Future of the Field? Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno Therapeutics again came under scrutiny last month following deaths in its JCAR015 trial. Two patients died from neurotoxicity-triggered cerebral edema, the same condition that killed […] December 14, 2016 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email
News and Trends 9 Dec 2016 Lifting the Chemo Fog: Virtual Reality has Medical Applications! Cancer can make life unbearable for some patients, but sometimes the treatment only adds to the pain. Could virtual reality treatments improve their lives? The vast majority of modern cancer therapies are focused on halting the progression and the spread of the disease to save the patient’s life. These treatments are usually aggressive, and approximately […] December 9, 2016 - 3 minutesmins - By Ekaterina Perets Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 The Munich Biotech Mafia expand to the US with a New TCR Startup TCR2 Therapeutics was backed by the Munich biotech mafia, a group of wealthy veteran biotech leaders that seem to be taking over the promising immuno-oncology field. TCR2 Therapeutics has kicked off with a €41.2M ($44.5M) Series A round led by MPM Capital in the US and F2 Ventures in London. The new company, based in Boston, […] December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email